Skip to main content

Table 2 Comparison of drugs and procedures between non-survivors and survivors on univariate analysis

From: Efficacy of extracorporeal membrane oxygenation for acute respiratory failure with interstitial lung disease: a case control nationwide dataset study in Japan

 

Non-survivors (n = 122)

Survivors (n = 42)

Crude odds ratio

95% confidence interval

Beta-lactam antibiotics

 Penicillin

65 (53.3)

21 (50.0)

1.140

0.565–2.300

 Cephem

60 (49.2)

21 (50.0)

0.968

0.480–1.951

 Carbapenem

99 (81.1)

30 (71.4)

1.722

0.767–3.865

 Macrolide

41 (33.6)

25 (59.5)

0.344

0.167–0.708

 Fluoroquinolone

68 (55.7)

21 (50.0)

1.259

0.624–2.542

 Tetracycline

18 (14.8)

5 (11.9)

1.281

0.444–3.695

 Trimethoprim-sulfamethoxazole

78 (63.9)

31 (73.8)

0.629

0.288–1.373

 Anti-MRSA drugs

83 (68.0)

24 (57.1)

1.596

0.777–3.279

 Anti- influenza drugs

10 (8.2)

9 (21.4)

0.327

0.123–0.873

 Anti-cytomegalovirus drugs

29 (23.8)

8 (19.0)

1.325

0.552–3.182

 Anti-fungal drugs

64 (52.5)

13 (31.0)

2.462

1.169–5.182

 Low-dose Steroid

116 (95.1)

41 (97.6)

0.472

0.055–4.035

 High-dose Steroid

105 (86.1)

33 (78.6)

1.684

0.686–4.133

 High-dose cyclophosphamide

38 (31.1)

6 (14.3)

2.714

1.055–6.986

 Other immunosuppressant

42 (34.4)

8 (19.0)

2.231

0.948–5.251

 Protease inhibitor

66 (54.1)

14 (33.3)

2.357

1.132–4.910

 Recombinant human soluble thrombomodulin

43 (35.2)

12 (28.6)

1.361

0.633–2.926

 Sivelestat sodium

64 (52.5)

18 (42.9)

1.471

0.726–2.983

 Duration of ECMO, day

14 (7.8–27.3)

7.5 (4.0–14.3)

1.043

1.010–1.077

 Duration of ventilation, day

20.0 (14.0–36.5)

13.5 (6.8–32.8)

1.012

0.991–1.033

 CHDF

79 (64.8)

16 (38.1)

2.985

1.446–6.165

  1. Data are expressed as number of patients (%)
  2. CHDF Continuous hemodialysis filtration, ECMO extracorporeal membrane oxygenation, MRSA methicillin-resistant Staphylococcus aureus